Can you check this one out? I hope its Relief Therapeudics RLFTF ($0.52 to $0.60) PITCH 34,900% sales surge for one company…
One Billion Doses of
Breakthrough “Super Vaccine”
Slated for Production!
https://pro.moneymappressinfo.com/p/ERNBPA1N/EERNWA90/?bsft_eid=cff9589e-528e-4e7e-a68f-0b19c0737d9a&bsft_aaid=8da0c2c8-9042-4b3e-bb76-8056465c4919&bsft_pid=b945d80e-d919-4d6f-ae0d-5956cf37ce77&utm_campaign=20201027_block_erntousmoneym_suppern&utm_medium=email&utm_content=20201027_block_erntousmoneym_suppern&bsft_clkid=54844cdb-d1c9-48da-bba1-c813b2d3feeb&bsft_uid=7c0afd43-6ed6-4e07-9b52-bbef050ad566&bsft_mid=6d3a3008-436a-40f1-a6ec-fe71cb4fbb96&bsft_pp=1&bsft_utid=7c0afd43-6ed6-4e07-9b52-bbef050ad566-USMONEYM&bsft_link_id=39&bsft_lx=5&bsft_tv=2&bsft_ek=2020-10-27T23%3A31%3A07Z&bsft_mime_type=html&customerNumber=000088324986&customerId=000088324986-000063299227&campaignId=794e7ddc-9de9-458a-afa6-0a6e847ae56f&r=eml&experimentId=cff9589e-528e-4e7e-a68f-0b19c0737d9a&vid=YhPDop&listName=USMONEYM&h=true
| Breaking Alert: Vaccine Production Now UnderWay
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Latest News. Maybe, perhaps
Lilly Strikes Collaboration With Swiss Biotech Basilea In Stomach Cancer Study
Eli Lilly And Co
LLY 0.02%
and Swiss biopharma Basilea Pharmaceutica announced a clinical trial collaboration and supply agreement for the use of the former’s anti-VEGFR2 antibody ramucirumab in the ongoing multi-cohort phase 1/2 study with the FGFR inhibitor derazantinib in advanced gastric cancer patients with FGFR genetic aberrations. Basilea is the sponsor of the study, while Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab, the companies said.
Separately, Lilly announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab, 700 mg, an investigational neutralizing antibody, for $375 million. The company has submitted a request for an emergency use authorization for bamlanivimab for the treatment of mild to moderate COVID-19 in high-risk patients to the FDA in early October.
The initial agreement is for delivery over the two months following an EUA and also provides the option for the U.S. government to purchase up to an additional 650,000 vials through June 30, 2021, under the same terms as the base agreement.
BPMUF
Basilea Pharmaceutica AG
54.00
0.00 (0.00%)
4:00 PM 10/27/20
Grey Market | Close